Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404753 | 1.00 | CTSK (0.42) | CTSKCTSSKMT2ACTSLKLK5 | |
| SCHEMBL5403570 | 0.83 | ATM (0.53) | CTSKCTSSCTSLKLK5 | |
| SCHEMBL6263984 | 0.81 | CTSK (0.42) | CTSKCTSSKMT2ACTSLKLK5 | |
| SCHEMBL20045534 | 0.79 | HPGD (0.46) | CTSKCTSSKMT2ACTSLMAPT | |
| SCHEMBL5412025 | 0.78 | CA1 (0.49) | CTSKCTSSCTSL | |
| SCHEMBL5416338 | 0.78 | ATM (0.51) | CTSKCTSSKMT2ACTSLKLK5 | |
| SCHEMBL5408458 | 0.78 | ATM (0.51) | CTSKCTSSKMT2ACTSLKLK5 | |
| SCHEMBL3182313 | 0.77 | GPR88 (0.49) | CTSKCTSSKMT2ACTSLNPC1 | |
| SCHEMBL3182322 | 0.77 | GPR88 (0.49) | CTSKCTSSKMT2ACTSLNPC1 | |
| SCHEMBL5406394 | 0.77 | CTSK (0.47) | CTSKCTSSKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | CTSK 4240/4885CTSS 3490/4885KMT2A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.